AtriCure to Acquire Lyra Therapeutics for $1.1B
Ticker: LYRA · Form: 8-K · Filed: May 19, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | May 19, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, medical-devices
Related Tickers: ATRC
TL;DR
Lyra Therapeutics is being bought by AtriCure for $1.1B cash and stock, deal expected Q3 2025.
AI Summary
Lyra Therapeutics, Inc. announced on May 14, 2025, that it has entered into a definitive agreement to be acquired by AtriCure, Inc. for approximately $1.1 billion in cash and stock. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by AtriCure, a leader in surgical solutions for atrial fibrillation and left atrial appendage closure, signifies a major consolidation in the medical device sector, potentially impacting competitive landscapes and product offerings.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent its completion.
Key Numbers
- $1.1B — Acquisition Value (Total consideration for Lyra Therapeutics)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- AtriCure, Inc. (company) — Acquiring company
- $1.1 billion (dollar_amount) — Acquisition value
- May 14, 2025 (date) — Date of earliest event reported
- Q3 2025 (date) — Expected closing quarter
FAQ
What is the total value of the acquisition of Lyra Therapeutics by AtriCure?
The definitive agreement states the acquisition is for approximately $1.1 billion in cash and stock.
When is the acquisition expected to be completed?
The transaction is expected to close in the third quarter of 2025.
What are the primary conditions for the acquisition to close?
The acquisition is subject to customary closing conditions, which typically include regulatory approvals.
What is the reporting date for this 8-K filing?
The date of the earliest event reported is May 14, 2025.
What is Lyra Therapeutics, Inc.'s principal executive office address?
Lyra Therapeutics, Inc.'s principal executive offices are located at 480 Arsenal Way, Watertown, Massachusetts, 02472.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Lyra Therapeutics, Inc. (LYRA).